Julie E Ledgerwood

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
  2. ncbi DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011
  3. ncbi A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
  4. ncbi A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1396-404. 2011
  5. ncbi DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e59340. 2013
  6. ncbi Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses
    Christopher J Obara
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA
    Virology 437:20-7. 2013
  7. ncbi Randomization to standard and concise informed consent forms: development of evidence-based consent practices
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    Contemp Clin Trials 33:895-902. 2012
  8. ncbi Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine
    Uzma N Sarwar
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, USA
    Travel Med Infect Dis 9:126-34. 2011
  9. ncbi Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:8954-67. 2011
  10. ncbi Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010

Collaborators

Detail Information

Publications10

  1. ncbi Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
    ..m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens...
  2. ncbi DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011
    ..We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improve antibody responses to inactivated influenza vaccination...
  3. ncbi A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
    ..This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses...
  4. ncbi A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1396-404. 2011
    ..There are no licensed vaccines to prevent WNV in humans. The safety and immunogenicity of a first-generation WNV DNA vaccine was demonstrated in a clinical trial and a similar DNA vaccine has been licensed for use in horses...
  5. ncbi DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e59340. 2013
    ..DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity...
  6. ncbi Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses
    Christopher J Obara
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA
    Virology 437:20-7. 2013
    ..Altogether, our studies suggest that cellular attachment factor expression is not a significant contributor to the potency of neutralizing antibodies to flaviviruses...
  7. ncbi Randomization to standard and concise informed consent forms: development of evidence-based consent practices
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    Contemp Clin Trials 33:895-902. 2012
    ....
  8. ncbi Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine
    Uzma N Sarwar
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, USA
    Travel Med Infect Dis 9:126-34. 2011
    ..This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine...
  9. ncbi Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:8954-67. 2011
    ..It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike...
  10. ncbi Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
    ..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies...